Scarica l'app Stockscreener
121.61
2.26%
2.69
Pre-mercato:
122.62
1.01
+0.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$118.92
Aprire:
$119.24
Volume 24 ore:
2.88M
Relative Volume:
1.79
Capitalizzazione di mercato:
$10.66B
Reddito:
$2.24B
Utile/perdita netta:
$385.90M
Rapporto P/E:
32.60
EPS:
3.73
Flusso di cassa netto:
$440.10M
1 W Prestazione:
+12.93%
1M Prestazione:
+30.41%
6M Prestazione:
-1.91%
1 anno Prestazione:
-15.07%
Intervallo 1D:
$116.57
$122.57
Intervallo di 1 settimana:
$105.45
$130.46
Portata 52W:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
121.61 | 10.66B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
155.99 | 69.76B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.06 | 48.12B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.76 | 45.75B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.60 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
306.92 | 13.67B | 2.76B | 1.11B | 898.10M | 22.77 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - Insider Monkey
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday - Insider Monkey
Neurocrine Bio stock target raised at Needham following earnings By Investing.com - Investing.com Canada
RBC Capital lifts Neurocrine Bio. stock target to $145 on sales momentum - Investing.com Nigeria
Neurocrine Biosciences (NBIX) Receives Price Target Raise from C - GuruFocus
Neurocrine Biosciences’ Earnings Call Highlights Growth Amid Challenges - TipRanks
NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Bio - GuruFocus
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May - PR Newswire
Guggenheim Ups Price Target for Neurocrine (NBIX) Amid Ingrezza Sales Performance | NBIX Stock News - GuruFocus
Neurocrine Biosciences (NBIX) Price Target Raised by RBC Capital | NBIX Stock News - GuruFocus
Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target - Benzinga
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target - Investing.com
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target By Investing.com - Investing.com India
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug - inkl
NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Biosciences | NBIX Stock News - GuruFocus
Neurocrine Biosciences (NBIX) Target Price Raised by UBS Analyst | NBIX Stock News - GuruFocus
Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong R - GuruFocus
BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating - marketscreener.com
Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong Results | NBIX Stock News - GuruFocus
Neurocrine Bio stock target raised at Needham following earnings - Investing.com
RBC Capital Increases Price Target for Neurocrine (NBIX) to $145 | NBIX Stock News - GuruFocus
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Seeking Alpha
UBS Elevates Neurocrine (NBIX) Price Target and Highlights Growth Prospects | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earni - GuruFocus
RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences (NBIX) Receives Price Target Raise from Canaccord Genuity | NBIX Stock News - GuruFocus
What 19 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga
Analyst Maintains Buy Rating on Neurocrine Biosciences (NBIX) with Raised Price Target | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Increased Following Strong Q1 Performance | NBIX Stock News - GuruFocus
S&P 500 Futures Drop in Premarket Trading; Neurocrine Biosciences, Regal Rexnord Lead - Barron's
Neurocrine Biosciences (NBIX) Price Target Increased by Canaccor - GuruFocus
Palantir, Ford, Tesla, Constellation Energy, Clorox, Hims & Hers, Neurocrine, AMD, and More Movers - Barron's
Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earnings Report | NBIX Stock News - GuruFocus
Palantir, Ford, Tesla, Clorox, Hims & Hers, Neurocrine, AMD, and More Market Movers - Barron's
Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ... By GuruFocus - Investing.com Canada
Neurocrine Biosciences Reports Strong Q1 2025 Results - TipRanks
Neurocrine: Q1 Earnings Snapshot - The Washington Post
Earnings call transcript: Neurocrine Biosciences Q1 2025 results miss EPS expectations - Investing.com Nigeria
Neurocrine Biosciences (NBIX) Surges 13% After Strong Q1 Results - GuruFocus
Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - Seeking Alpha
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates - Yahoo Finance
Neurocrine Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Neurocrine Biosciences stock soars on strong INGREZZA guidance By Investing.com - Investing.com South Africa
Neurocrine Biosciences stock soars on strong INGREZZA guidance - Investing.com
NBIX Reports Strong Q1 Revenue and Reaffirms Sales Guidance | NBIX Stock News - GuruFocus
Earnings Flash (NBIX) Neurocrine Biosciences Posts Q1 Revenue $572.6M, vs. FactSet Est of $559.6M - marketscreener.com
Earnings Flash (NBIX) Neurocrine Biosciences Reports Q1 Adjusted EPS $0.70 - marketscreener.com
Neurocrine Biosciences Inc Q1 Profit Decreases, Misses Estimates - Nasdaq
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.42%
23.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):